Bristol-Myers Squibb: Performance
 
Performance

The most important measure of Bristol-Myers Squibb’s success as a next-generation BioPharma leader is the difference we make in the lives of patients. In addition, our ability to ensure the sustainability of our business is often measured by our sales growth.

The company's products are sold principally to the wholesale and retail trade. Certain products are also sold to other drug manufacturers, hospitals and the medical profession. Bristol-Myers Squibb is also committed to improving access to our medicines for patients who are unable to afford them.

Bristol-Myers Squibb's worldwide sales from continuing operations are shown in the following table:

2012 2013 2014 2013-2014 change
$17.6 billion $16.4 billion $15.9 billion -3%

Bristol-Myers Squibb products are available in virtually every country in the world. The company's largest markets include the United States, France, Canada, Japan, Italy, Spain, Germany, China and the United Kingdom.


2014 Sales by Region
United States 49%
Europe 23%
Rest of the World 21%
Other* 7%

*Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.


In 2014, we invested $4.5 billion on pharmaceutical R&D, an amount that represents 28 percent of our pharmaceutical sales.

Taxes Paid

Bristol-Myers Squibb made provision for $352 million in income taxes in 2014. For more information on taxes paid, refer to the Notes to Consolidated Financial Statements of our Annual Report.

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.